Stocks
Neurocrine Nears $2.5B-Plus Soleno Acquisition
Neurocrine Biosciences is in advanced talks to acquire Soleno Therapeutics for over $2.5 billion, potentially valuing Soleno shares in the low-to-mid $50s,...
Neurocrine Biosciences is in advanced talks to acquire Soleno Therapeutics for over $2.5 billion, potentially valuing Soleno shares in the low-to-mid $50s,...